Composition used for improving sialyl level of recombinant human type II tumor necrosis factor receptor-antibody fusion protein

A composition and cofactor technology, applied in the biological field, can solve problems such as human beings that have not yet been regulated, and achieve the effects of being suitable for large-scale production, increasing the speed of enzyme reactions, and increasing the supply of substrates

Active Publication Date: 2017-01-11
HISUN BIOPHARMACEUTICAL CO LTD +1
View PDF8 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, at this stage, there is no effective measure to regulate the sialylation level of recombinant human tumor necrosis factor receptor type II-antibody fusion protein

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition used for improving sialyl level of recombinant human type II tumor necrosis factor receptor-antibody fusion protein
  • Composition used for improving sialyl level of recombinant human type II tumor necrosis factor receptor-antibody fusion protein
  • Composition used for improving sialyl level of recombinant human type II tumor necrosis factor receptor-antibody fusion protein

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] Example 1 is applied to the commercial serum-free medium EX-CELL produced by SAFC Biosciences in the United States in the batch culture process TM Composition of 302CHO for increasing the level of sialylation of recombinant human tumor necrosis factor receptor type II-antibody fusion protein.

[0058] Eighteen compositions for improving the sialylation level of recombinant human tumor necrosis factor receptor type II-antibody fusion protein are provided in this example (Table 2), containing manganese chloride tetrahydrate, galactose, glucosamine, N- Acetylmannose, N-acetylglucosamine, uracil, dexamethasone, and hydrocortisone.

[0059] The preparation method of the composition in this embodiment is as follows: fully dissolving the recipe amounts of manganese chloride tetrahydrate, galactose, glucosamine, N-acetylmannose, N-acetylglucosamine and uracil in pyrogen-free ultrapure water , Dissolve the prescribed amount of dexamethasone and hydrocortisone in 99% ethanol so...

Embodiment 2

[0069] Example 2 In the process of fed-batch culture, the composition for increasing the sialylation level of recombinant human tumor necrosis factor receptor type II-antibody fusion protein was applied to the CD optimal commercial basal medium developed by the American Life techonology company.

[0070] The composition used in this example for improving the sialylation level of recombinant human tumor necrosis factor receptor type II-antibody fusion protein contains:

[0071] Galactose: 30mmol / L

[0072] Glucosamine: 20mmol / L

[0073] N-acetylmannose: 20mmol / L

[0074] N-acetylglucosamine: 20mmol / L

[0075] Uracil: 20mmol / L

[0076] Manganese chloride tetrahydrate: 0.1mmol / L

[0077] Dexamethasone: 0.1mmol / L and

[0078] Hydrocortisone: 0.1 mmol / L.

[0079] The preparation method of the composition in this embodiment is as follows: fully dissolving the recipe amounts of manganese chloride tetrahydrate, galactose, glucosamine, N-acetylmannose, N-acetylglucosamine and ura...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a composition used for improving the sialyl level of a recombinant human type II tumor necrosis factor receptor-antibody fusion protein. The composition comprises galactose (10-100mmol / L), glucosamine (1-50mmol / L), N-acetylmannosamine (1-50mmol / L), N-acetylglucosamine (1-50mmol / L), uracil (1-50mmol / L), tetrahydrate manganese chloride (0.01-1mmol / L), dexamethasone (0.01-1mmol / L) and hydrocortisone (0.01-1mmol / L). After the composition disclosed by the invention is added into a culture medium, the sialyl level of the recombinant human type II tumor necrosis factor receptor-antibody fusion protein produced by a large-scale animal cell culture technology can be obviously improved, so that the stability of the recombinant human type II tumor necrosis factor receptor-antibody fusion protein is improved.

Description

technical field [0001] The present invention belongs to the field of biotechnology, in particular, the present invention relates to a composition for improving the sialylation level of recombinant human type II tumor necrosis factor receptor-antibody fusion protein. [0002] technical background [0003] Since the beginning of the 21st century, life sciences and biotechnology have become research and development hotspots in many countries, and the development level of the modern biotechnology industry is one of the important symbols of international competitiveness. Animal cell expression system and its large-scale culture technology are the most important production systems and core technologies in the biotechnology drug and biological product industry at this stage and for a long period of time in the future. Its products include various antibodies, recombinant proteins, human, livestock and poultry viruses. vaccines, etc. Among them, recombinant human type II tumor necros...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12P21/00C12R1/91
Inventor 邓献存王海彬范里邓全宇万宇翔潘洪辉徐胜缪仕伟白骅
Owner HISUN BIOPHARMACEUTICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap